Drug conjugate composition
AssigneeImmunoGen, Inc.
InventorsGodfrey AMPHLETT, Wei ZHANG, Michael FLEMING, Hung-Wei CHIH
Life of this patent
Estimating the term…
Abstract
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
Claims30
A composition comprising (i) a conjugate comprising an antibody chemically coupled to a maytansinoid, (ii) a buffering agent selected from the group consisting of a citrate buffer, an acetate buffer, a succinate buffer, and a histidine buffer, (iii) a first excipient selected from the group consisting of glycerol, dimethyl sufoxide, polyethylene glycol, dextran, glucose, trehalose, and sucrose, (iv) a second excipient selected from the group consisting of glycine, mannitol, and dextran, (v) a surfactant, and (vi) water, wherein the composition has a pH of about 5-6.
Dependencies are inferred from the claim text.